Health
DATROWAY® Approved in the U.S. as First TROP2 Directed Therapy for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
TOKYO & BASKING RIDGE, N.J., June 23, 2025--DATROWAY® Approved in the U.S. as First TROP2 Directed Therapy for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
About this update from Daiichi Sankyo Company, Limited
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":474,"url":"https://media.zenfs.com/en/business-wire.com/cb5fa8c5f3e63a883c50870d079bf381"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/JO_96p3WVMW0rqUlSZ_FWQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTk0ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/cb5fa8c5f3e63a883c50870d079bf381","width":480,"height":474}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Based on TROPION-Lung05 phase 2 trial results and supported by data from the TROPION-Lung01 phase 3 trial","length":105,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Second U.S. approval for Daiichi Sankyo and AstraZeneca’s DATROWAY in less than six months","length":90,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":195,"olType":false},{"type":"text","content":"TOKYO & BASKING RIDGE, N.J., June 23, 2025--(BUSINESS WIRE)--DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy. This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DoR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial.","length":597,"tagName":"p"},{"type":"text","content":"DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN).","length":231,"tagName":"p"},{"type":"text","content":"The approval follows Priority Review and Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) based on subgroup results from the TROPION-Lung05 phase 2 and TROPION-Lung01 phase 3 trials.","length":213,"tagName":"p"},{"type":"text","content":"In TROPION-Lung05 and TROPION-Lung01, DATROWAY demonstrated a confirmed ORR of 45% (95% confidence interval [CI]: 35-54) in patients (n=114) with previously treated locally advanced or metastatic EGFR-mutated NSCLC...